SCHEMBL5214784

SCHEMBL5214784

O=Cc1ccc(OCCc2ccccc2)c(CO)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.46
PTGES O14684 2/20 0.45
ALOX5 P09917 2/20 0.45
PPARG P37231 2/20 0.45
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
NPC1 O15118 1/20 0.43
CYP2C9 P11712 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
FDPS P14324 1/20 0.43
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
HPGD P15428 2/20 0.42
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
C5AR1 P21730 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932209 0.86 MAOA (0.57) MAOAMAOBNPC1RAB9A
SCHEMBL4576841 0.84 FDPS (0.57) AKR1C3MAOAMAOBNPC1CYP2C9
SCHEMBL5214421 0.84 MAOA (0.56) AKR1C3PTGESALOX5PPARGMAOA
SCHEMBL420250 0.83 TTR (0.52) AKR1C3ALOX5MAOAMAOBNPC1
SCHEMBL77752 0.82 FDPS (0.50) NPC1CYP2C9RAB9ANPSR1FDPS
SCHEMBL2933672 0.81 CYP2C9 (0.58) AKR1C3PTGESALOX5PPARGNPC1
SCHEMBL1299319 0.80 HPGD (0.61) AKR1C3PPARGMAOAMAOBNPC1
SCHEMBL5215514 0.80 ALDH1A1 (0.44) AKR1C3PTGESALOX5PPARGMAOA
SCHEMBL7255384 0.79 AKR1C3 (0.48) AKR1C3PTGESALOX5PPARGNPC1
SCHEMBL9077155 0.79 TACR2 (0.54) AKR1C3MAOAMAOBNPSR1FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313471-B1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS UCB SA (BE) 2007-04-11 EP disclosed
EP-1313471-B1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS UCB SA (BE) 2007-04-11 EP disclosed
US-7105554-B2 Benzylidene thiazolidinediones and their use as antimycotic agents OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2006-09-12 US disclosed
US-20040006112-A1 Benzylidene thiazolidinediones and their use as antimycotic agents OXFORD GLYCOSCIENCES (UK) LTD (GB) 2004-01-08 US disclosed
EP-1313471-A1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS Oxford GlycoSciences (UK) Limited (GB) 2003-05-28 EP disclosed
WO-2002017915-A1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006112-A1 Benzylidene thiazolidinediones and their use as antimycotic agents SLC5A2, OXSR1, SLC5A1 AKR1C3 505/4885PTGES 4231/4885ALOX5 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.